| Product Code: ETC9214219 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Serbia Neoantigens Market Overview |
3.1 Serbia Country Macro Economic Indicators |
3.2 Serbia Neoantigens Market Revenues & Volume, 2021 & 2031F |
3.3 Serbia Neoantigens Market - Industry Life Cycle |
3.4 Serbia Neoantigens Market - Porter's Five Forces |
3.5 Serbia Neoantigens Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Serbia Neoantigens Market Revenues & Volume Share, By Therapeutic Specialty, 2021 & 2031F |
3.7 Serbia Neoantigens Market Revenues & Volume Share, By Line of Therapy, 2021 & 2031F |
3.8 Serbia Neoantigens Market Revenues & Volume Share, By End users, 2021 & 2031F |
4 Serbia Neoantigens Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Serbia |
4.2.2 Growing investments in healthcare infrastructure and RD |
4.2.3 Rising awareness about personalized medicine and targeted therapies |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for neoantigen therapies |
4.3.2 Limited availability of skilled professionals in the field of immunotherapy |
4.3.3 High costs associated with neoantigen therapy development and administration |
5 Serbia Neoantigens Market Trends |
6 Serbia Neoantigens Market, By Types |
6.1 Serbia Neoantigens Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Serbia Neoantigens Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Serbia Neoantigens Market Revenues & Volume, By Combination Therapy, 2021- 2031F |
6.1.4 Serbia Neoantigens Market Revenues & Volume, By Mono Therapy, 2021- 2031F |
6.2 Serbia Neoantigens Market, By Therapeutic Specialty |
6.2.1 Overview and Analysis |
6.2.2 Serbia Neoantigens Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.2.3 Serbia Neoantigens Market Revenues & Volume, By Urinary System Cancer, 2021- 2031F |
6.2.4 Serbia Neoantigens Market Revenues & Volume, By Melanoma, 2021- 2031F |
6.2.5 Serbia Neoantigens Market Revenues & Volume, By Liver Cancer, 2021- 2031F |
6.2.6 Serbia Neoantigens Market Revenues & Volume, By Head and Neck Cancer, 2021- 2031F |
6.2.7 Serbia Neoantigens Market Revenues & Volume, By Blood and Bone Marrow Cancer, 2021- 2031F |
6.3 Serbia Neoantigens Market, By Line of Therapy |
6.3.1 Overview and Analysis |
6.3.2 Serbia Neoantigens Market Revenues & Volume, By First Line, 2021- 2031F |
6.3.3 Serbia Neoantigens Market Revenues & Volume, By Second Line, 2021- 2031F |
6.3.4 Serbia Neoantigens Market Revenues & Volume, By Later Lines, 2021- 2031F |
6.4 Serbia Neoantigens Market, By End users |
6.4.1 Overview and Analysis |
6.4.2 Serbia Neoantigens Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Serbia Neoantigens Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 Serbia Neoantigens Market Revenues & Volume, By Specialty Centers, 2021- 2031F |
6.4.5 Serbia Neoantigens Market Revenues & Volume, By Others, 2021- 2031F |
7 Serbia Neoantigens Market Import-Export Trade Statistics |
7.1 Serbia Neoantigens Market Export to Major Countries |
7.2 Serbia Neoantigens Market Imports from Major Countries |
8 Serbia Neoantigens Market Key Performance Indicators |
8.1 Number of clinical trials involving neoantigen therapies in Serbia |
8.2 Rate of adoption of personalized medicine in oncology |
8.3 Investment trends in biotech companies focusing on neoantigen research and development |
8.4 Number of research publications related to neoantigens in Serbia |
8.5 Patient outcomes and survival rates following neoantigen therapy treatments |
9 Serbia Neoantigens Market - Opportunity Assessment |
9.1 Serbia Neoantigens Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Serbia Neoantigens Market Opportunity Assessment, By Therapeutic Specialty, 2021 & 2031F |
9.3 Serbia Neoantigens Market Opportunity Assessment, By Line of Therapy, 2021 & 2031F |
9.4 Serbia Neoantigens Market Opportunity Assessment, By End users, 2021 & 2031F |
10 Serbia Neoantigens Market - Competitive Landscape |
10.1 Serbia Neoantigens Market Revenue Share, By Companies, 2024 |
10.2 Serbia Neoantigens Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here